Genomic Profiling Identified a Mutational Signature Related to Female in Nonsmoking Lung Adenocarcinoma
Cancer Research and Treatment · 2026
DOI: 10.4143/crt.2025.489 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2026. Verfasst von Jinman Zhuang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Mutation, Adenocarcinoma of Lung, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of Fujian province, Innovation of science and technology of Fujian province, Health Commission's Program for Cultivating Middle-aged.
Abstract (Originalsprache)
Purpose
This study aimed to illustrate mutational characteristics in nonsmoking lung adenocarcinoma (LUAD) and to explore its relationship with clinical factors.Materials and Methods We included 86 nonsmokers with LUAD and downloaded the clinical information, whole exome sequencing, and RNA sequencing data from cBioPortal and The Cancer Genome Atlas (TCGA) website. NMF algorithm, “SomaticSignatures,” and “DeconstructSigs” were used to reconstruct and infer new mutational signature. The similarity between Catalogue of Somatic Mutations in Cancer (COSMIC) and reconstructed mutational signature was measured by cosine similarity. The enrichment status of signaling pathways was derived by Gene Set Enrichment Analysis. “pRRophetic” package was used to predict the sensitivity of adjuvant drug for cancer treatments.
Results
The most frequent driver genes in nonsmoking LUAD were epidermal growth factor receptor (EGFR) (59% in cBioPortal cohort, 68% in Fujian nonsmoking LUAD cohort). We identified three new mutation signatures of LUAD in nonsmokers and identified S2 as the most enriched signature in these nonsmokers with LUAD. In cBioPortal and Fujian nonsmoking LUAD cohort, the proportion of S2 was higher in females (p < 0.05) and patients with tumor mutational burden (TMB) (p < 0.01). Similar results were observed in nonsmoking TCGA-LUAD cohort (pfemale=0.0013, pTMB < 0.001). OXIDATIVE_PHOSPHORYLATION signaling pathway was most enriched in S2-enriched group (NES=1.63). S2-enriched group had higher mutation rate of EGFR (p=0.003) and more drug sensitivity to metformin (p=0.035).
Conclusion
We identified a new mutational signature (S2) which is most enriched in LUAD in nonsmokers and related to female and low-TMB. S2 mutational signature may help reveal female-related mutagenesis mechanisms and develop strategies for therapeutic of never-smoker lung adenocarcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China.
- Department of Pulmonary and Critical Care Medicine, Fujian Provincial Hospital, Fujian Shengli Medical College, Fujian Medical University, Fuzhou, China.
- Department of Bioinformatics, Fujian Key Laboratory of Medical Bioinformatics, School of Medical Technology and Engineering, Fujian Medical University, Fuzhou, China.
- Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China. i.fei.he@fjmu.edu.cn.
- Fujian Provincial Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, China. i.fei.he@fjmu.edu.cn.
- Fujian Digital Tumor Data Research Center, Fuzhou, China. i.fei.he@fjmu.edu.cn.
Förderung
- National Natural Science Foundation of Fujian province
- Innovation of science and technology of Fujian province
- Health Commission's Program for Cultivating Middle-aged
- Young Backbone Talents of Fujian province
- Health Commission’s Program for Cultivating Middle-aged
Zitieren
APA
Zhuang, J., Yang, Y., Chen, X., Zheng, G., Shen, X., He, F., & Xie, B. (2026). Genomic Profiling Identified a Mutational Signature Related to Female in Nonsmoking Lung Adenocarcinoma. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.489
Vancouver
Zhuang J, Yang Y, Chen X, Zheng G, Shen X, He F, et al. Genomic Profiling Identified a Mutational Signature Related to Female in Nonsmoking Lung Adenocarcinoma. Cancer Research and Treatment. 2026. doi:10.4143/crt.2025.489
BibTeX
@article{Zhuang2026,
author = {Zhuang, Jinman and Yang, Yongsheng and Chen, Xuezhen and Zheng, Guanying and Shen, Xiaopei and He, Fei and Xie, Baosong},
title = {Genomic Profiling Identified a Mutational Signature Related to Female in Nonsmoking Lung Adenocarcinoma},
journal = {Cancer Research and Treatment},
year = {2026},
doi = {10.4143/crt.2025.489}
}
EUVIMED